Curated News
By: NewsRamp Editorial Staff
July 28, 2026

Greenland Mines Secures Canadian Patent for Klotho Gene Therapies Targeting Neurodegenerative Diseases

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Greenland Mines secures Canadian patent for Klotho gene therapies, bolstering its IP portfolio and competitive edge in treating Alzheimer's and ALS.
  • The Canadian patent covers 42 claims for s-KL RNA splice variant synthesis, delivery methods, and applications across neurological disorders like Parkinson's.
  • Greenland Mines' Klotho gene therapies aim to combat neurodegenerative diseases, potentially improving cognition and memory for millions worldwide.
  • Greenland Mines holds patents in US, China, Europe; KLTO-202 advances to GMP manufacturing with regulatory talks later this year.

Impact - Why it Matters

This patent strengthens Greenland Mines' position in the rapidly growing gene therapy market, particularly for Alzheimer’s, Parkinson’s, and ALS. For investors, it signals potential revenue streams from a diversified biotech pipeline alongside mining operations. For patients and caregivers, it offers hope for new treatments targeting memory and cognition. The advancement of KLTO-202 to GMP manufacturing and upcoming regulatory interactions could accelerate clinical development, making this a pivotal moment for the company and the neurodegenerative disease landscape.

Summary

Greenland Mines (NASDAQ: GRML) has secured a significant patent from Innovation, Science and Economic Development Canada for Klotho-based gene therapies targeting cognition, memory, and neurodegenerative diseases. The patent, exclusively licensed by the company, covers the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims addressing synthesis, delivery methods, and applications across disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. This Canadian patent expands Greenland Mines’ intellectual property portfolio for Klotho-based therapeutics, complementing existing patents in the United States, China, and Europe. The company announced that process development and manufacturing for lead candidate KLTO-101 will start in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.

Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project, and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is to build a multi-asset platform with exposure to rare earth magnet materials, precious metals, and midstream processing opportunities, while advancing its North Atlantic Critical Metals Corridor vision. The patent news underscores the company’s dual focus on mining and biotechnology, leveraging Klotho gene therapies to address major neurological conditions.

For more details, the full press release is available at https://ibn.fm/x2pHA. The company also invites investors to stay updated via its newsroom at https://ibn.fm/GRML. This development highlights Greenland Mines’ commitment to innovation in both the mining and biotech sectors, positioning it as a key player in critical materials and neurodegenerative disease therapies.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Greenland Mines Secures Canadian Patent for Klotho Gene Therapies Targeting Neurodegenerative Diseases

blockchain registration record for this content.